This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Eli Lilly & Company
Drug Names(s): INCB28050, LY3009104, LY-3009104
Description: INCB28050 is a follow-on janus-associated kinase inhibitor. Janus-associated kinases (JAK) are enzymes that mediate signaling of several important drivers of inflammatory diseases, myeloproliferative disorders (MPDs) and malignancies. INCB18424 and INCB28050 inhibit JAK 1 and 2. INCB28050 was chosen as the lead JAK inhibitor for inflammatory disorders based upon having a longer half-life and being a more potent inhibitor of JAK 1 and 2 than INCB18424.
Deal Structure: INCB28050 was originally developed by Incyte.
Incyte and Eli Lilly
In December 2009, Eli Lilly and Incyte Corporation announced that they entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of INCB28050 and certain follow on compounds for inflammatory and autoimmune diseases. Under the terms of the agreement, Lilly will receive worldwide rights to develop and commercialize INCB28050 as an oral treatment for all inflammatory conditions. In exchange for these rights, Incyte will receive an initial payment of $90 million and is eligible for up to $665 million in additional potential development, regulatory, and commercialization milestones, as well as tiered, double-digit royalty payments on future global sales with rates ranging up to twenty percent if a product is successfully commercialized.
Incyte will retain the option to co-develop its JAK1/JAK2 inhibitors with Lilly on a compound-by-compound and...See full deal structure in Biomedtracker
Partners: Incyte Corporation
Additional information available to subscribers only: